title: Single-agent vinorelbine in pretreated breast cancer patients: comparison of two different schedules.
abstract: This retrospective study compared toxicity and activity of vinorelbine according to two schedules with different projected dose intensities in heavily pretreated breast cancer patients. Forty patients were assessable for toxicity and activity in each group; group A received vinorelbine 25 mg/m2 week + lenograstim (150 microg/m2 s.c. on day 3); group B received 25 mg/m2 on days 1 and 8 every 3 weeks. The projected dose intensity was 25 mg/m2/week and 16.6 mg/m2/week, and delivered dose intensity 95.2% and 94.5% in group A and B, respectively. Grade 3-4 afebrile neutropenia was recorded in 25% and 37.5% of patients in A and B, respectively. Overall response rate, 52.5% and 35%; no change, 35% and 40%; progression of disease, 12.5% and 25% in A and B, respectively. Median duration of the response was 10 months for group A and 7 months for B. Median time to progression: 9.0 months and 4.0 months for A and B, respectively. At a median follow-up of 45 months for group A and 19 months for group B, median overall survival was 19 months and 16, respectively. In conclusion the results of the study showed that dose intensity of vinorelbine could have an improvement in terms of time to progression in pretreated advanced breast cancer.
authors.affiliation: Department of Medical Oncology, Regina Elena Cancer Institute, Rome, Italy.
authors.forename: E
authors.initials: E
authors.lastname: Terzoli
authors.forename: C
authors.initials: C
authors.lastname: Nisticò
authors.forename: A
authors.initials: A
authors.lastname: Fabi
authors.forename: M
authors.initials: M
authors.lastname: Milella
authors.forename: E
authors.initials: E
authors.lastname: Bria
authors.forename: A M
authors.initials: AM
authors.lastname: D'Ottavio
authors.forename: A
authors.initials: A
authors.lastname: Vaccaro
authors.forename: B
authors.initials: B
authors.lastname: Vanni
authors.forename: C
authors.initials: C
authors.lastname: Garufi
authors.forename: V
authors.initials: V
authors.lastname: Ferraresi
authors.forename: D
authors.initials: D
authors.lastname: Giannarelli
authors.forename: P
authors.initials: P
authors.lastname: Papaldo
authors.forename: P
authors.initials: P
authors.lastname: Carlini
authors.forename: F
authors.initials: F
authors.lastname: Izzo
authors.forename: F
authors.initials: F
authors.lastname: Cognetti
mesh_terms: D000276:Adjuvants, Immunologic / Q000008:administration & dosage; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000972:Antineoplastic Agents, Phytogenic / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols; D001859:Bone Neoplasms / Q000188:drug therapy / Q000556:secondary; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology; D018450:Disease Progression; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage; D006801:Humans; D000078224:Lenograstim; D008113:Liver Neoplasms / Q000188:drug therapy / Q000556:secondary; D008175:Lung Neoplasms / Q000188:drug therapy / Q000556:secondary; D008875:Middle Aged; D011994:Recombinant Proteins / Q000008:administration & dosage; D012189:Retrospective Studies; D016879:Salvage Therapy; D013997:Time Factors; D014747:Vinblastine / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D000077235:Vinorelbine
chemical_list: D000276:Adjuvants, Immunologic; D000972:Antineoplastic Agents, Phytogenic; D011994:Recombinant Proteins; D016179:Granulocyte Colony-Stimulating Factor; D014747:Vinblastine; D000078224:Lenograstim; D000077235:Vinorelbine